Serum S100A12 and progression of coronary artery calcification over 4 years in hemodialysis patients

American Journal of Nephrology

Volumn 42, Issue 1, 2015, Pages 4-13

  Wang, Yin Na ^a   Sun, Yi ^a   Wang, Ying ^a   Jia, Yan Li ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Coronary artery calcification; Hemodialysis; S100A12; Vascular calcification

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALGRANULIN C; FERRITIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; TRIACYLGLYCEROL; VITAMIN D; S100A12 PROTEIN, HUMAN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEPHROSCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CALCINOSIS; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; MIDDLE AGED; PROSPECTIVE STUDY; RADIOGRAPHY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SEVERITY OF ILLNESS INDEX; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

AGED; CALCINOSIS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; S100A12 PROTEIN; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 84939487271     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000438869     Document Type: Article

References (32)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
2. Collins AJ. Cardiovascular mortality in endstage renal disease. Am J Med Sci 2003; 325: 163-167.
3. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
4. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
5. Yang Z, Tao T, Raftery M, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001; 69: 986-994.
6. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Nakajima F, Nagahara M, Urakami M, Iwasaka T, Matsubara H. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009; 29: 18-24.
7. Yang Z, Yan WX, Cai H, Tedla N, Armishaw C, Di Girolamo N, Wang HW, Hampartzoumian T, Simpson JL, Gibson PG, Hunt J, Hart P, Hughes JM, Perry MA, Alewood PF, Geczy CL. S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity. J Allergy Clin Immunol 2007; 119: 106-114.
8. Mahajan N, Malik N, Bahl A, Dhawan V. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand ENRAGE in non-Diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 2009; 207: 597-602.
9. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (ENRAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012; 220: 208-214.
10. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, Maki N, Iida K, Iwamoto N, Ono T, Matsuoka E, Kishimoto N, Tamagaki K, Matsubara H, Kosaki A. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 718-723.
11. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Barany P, Heimburger O, Stenvinkel P, Lindholm B. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 2213-2219.
12. Ozkok A, Kekik C, Karahan GE, Sakaci T, Ozel A, Unsal A, Yildiz A. FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrol 2013; 14: 241.
13. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832.
14. Rumberger JA. Using noncontrast cardiac CT and coronary artery calcification measurements for cardiovascular risk assessment and management in asymptomatic adults. Vasc Health Risk Manag 2010; 6: 579-591.
15. Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, Fitzgerald O, Roth J. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 1383-1389.
16. Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, Sorg C, Roth J. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 2003; 361: 1270-1272.
17. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52: 847-853.
18. Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Barany P, Stenvinkel P, Lindholm B. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease stage 5 patients. Nephrol Dial Transplant 2015; 30: 84-91.
19. Hara M, Ando M, Morito T, Nokiba H, Iwasa Y, Tsuchiya K, Nitta K. S100A12 gene expression is increased in peripheral leukocytes in chronic kidney disease stage 4-5 patients with cardiovascular disease. Nephron Clin Pract 2013; 123: 202-208.
20. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, OBrien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011. Circulation 2011; 124: 1783-1791.
21. Hofmann Bowman MA, Gawdzik J, Bukhari U, Husain AN, Toth PT, Kim G, Earley J, Mc-Nally EM. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol 2011; 31: 337-344.
22. Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA. Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol 2011; 33: 250-259.
23. Yan L, Mathew L, Chellan B, Gardner B, Earley J, Puri TS, Hofmann Bowman MA. S100/calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-Dependent manner. Arterioscler Thromb Vasc Biol 2014; 34: 1399-1411.
24. Kim HS, Chung W, Kim AJ, Ro H, Chang JH, Lee HH, Jung JY. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels. Nephrology (Carlton) 2013; 18: 777-782.
25. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91: 4628-4634.
26. Myles A, Viswanath V, Singh YP, Aggarwal A. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels. J Rheumatol 2011; 38: 1994-1999.
27. Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol 2004; 24: 1272-1277.
28. Raggi P, Cooil B, Shaw LJ, Aboulhson J, Takasu J, Budoff M, Callister TQ. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. Am J Cardiol 2003; 92: 827-829.
29. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1241-1248.
30. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
31. Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, Ozel A, Unsal A, Yildiz A. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol 2012; 7: 965-973.
32. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-Term hemodialysis. Am J Kidney Dis 2003; 42: 303-309.